Bausch & Lomb vs. Gland Pharma: Consent Judgment Resolves Glaucoma Drug Patent Dispute

Case Overview

The Parties

Patents at Issue

This landmark pharmaceutical patent case involved four U.S. patents protecting the latanoprostene bunod compound and its ophthalmic formulation:

• • U.S. Patent No. 7,273,946 — Latanoprostene bunod compound
• • U.S. Patent No. 7,629,345 — Latanoprostene bunod compound derivatives
• • U.S. Patent No. 7,910,767 — Ophthalmic formulations
• • U.S. Patent No. 8,058,467 — Ophthalmic formulations and methods of use

Litigation Timeline & Procedural History

The complaint was filed on June 30, 2022, in the U.S. District Court for the District of New Jersey. The case, presided over by Chief Judge Stanley R. Chesler, proceeded through approximately two and a half years before a consent judgment was entered on January 22, 2025. This timeline is typical for Hatch-Waxman resolutions where parties often negotiate authorized generic entry dates to avoid prolonged litigation.

The Verdict & Legal Analysis

Outcome

On January 22, 2025, Chief Judge Chesler entered a consent judgment resolving all claims with prejudice. The court granted permanent injunctive relief, enjoining Gland Pharma from infringing the four asserted patents by commercializing their ANDA product, except as specifically authorized under a separate Settlement Agreement. This outcome is consistent with negotiated Hatch-Waxman resolutions, often involving future authorized generic entry.

Key Legal Issues and Significance

This action arose under the Hatch-Waxman Act. Gland Pharma’s Paragraph IV certification triggered Bausch & Lomb’s infringement suit. The consent judgment’s broad injunctive relief, covering Gland Pharma’s affiliates and assigns, aims to prevent circumvention. While direct precedential value is limited, the case reinforces the effectiveness of layered patent portfolios covering both compound and formulation claims in deterring generic competition. The retention of jurisdiction clause ensures judicial oversight of the settlement terms.

Strategic Takeaways

For Patent Holders: Building multi-patent portfolios (compound, formulation, methods) substantially increases ANDA litigation leverage.

For Accused Infringers: Early assessment of settlement economics is critical, especially when design-around options are limited. Negotiated entry dates can be a rational alternative to protracted litigation.

For R&D Teams: Rigorous Freedom-to-Operate (FTO) analysis against established patent estates is crucial before investing in ophthalmic drug development.

What patents were involved in Bausch & Lomb v. Gland Pharma?

Four U.S. patents were asserted: Nos. 7,273,946; 7,629,345; 7,910,767; and 8,058,467 — collectively covering the latanoprostene bunod compound and ophthalmic formulations used in Vyzulta®.

What was the basis for the consent judgment in this case?

The parties reached a negotiated resolution under a Settlement Agreement, with the court entering a consent judgment enjoining Gland Pharma from infringing the four asserted patents except as specifically authorized under that agreement.

How does this case affect ophthalmic drug patent litigation?

It reinforces the strategic value of layered pharmaceutical patent portfolios in ANDA litigation and signals that nitric oxide-donating ophthalmic compound patents remain enforceable barriers to generic entry in the mid-2020s.